Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker

Hailan Liu, Jing Yuan Liu, Xi Wu, Jian-Ting Zhang

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Human fatty acid synthase (FASN) is a 270-kDa cytosolic dimeric enzyme that is responsible for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for diagnosis and prognosis of human cancers. Recent studies showed that FASN is an oncogene and inhibition of FASN effectively and selectively kill cancer cells. With recent publications of the FASN crystal structure and the new development of FASN inhibitors, targeting FASN opens a new window of opportunity for metabolically combating cancers. In this article, we will review critically the recent progresses in understanding the structure, function, and the role of FASN in cancers and pharmacologically targeting FASN for human cancer treatment.

Original languageEnglish
Pages (from-to)69-89
Number of pages21
JournalInternational Journal of Biochemistry and Molecular Biology
Volume1
Issue number1
StatePublished - 2010

Fingerprint

Fatty Acid Synthases
Biochemistry
Molecular biology
Molecular Biology
Pharmacology
Neoplasms
Therapeutics
Oncology
Palmitates
Oncogenes
Crystal structure
Cells
Enzymes

Keywords

  • Cancer
  • Diagnosis
  • Drug resistance
  • Fatty acid synthase
  • Inhibitors
  • Prognosis

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. / Liu, Hailan; Liu, Jing Yuan; Wu, Xi; Zhang, Jian-Ting.

In: International Journal of Biochemistry and Molecular Biology, Vol. 1, No. 1, 2010, p. 69-89.

Research output: Contribution to journalArticle

@article{f1096e23fe424fec9734e97ee51c5ed6,
title = "Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker",
abstract = "Human fatty acid synthase (FASN) is a 270-kDa cytosolic dimeric enzyme that is responsible for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for diagnosis and prognosis of human cancers. Recent studies showed that FASN is an oncogene and inhibition of FASN effectively and selectively kill cancer cells. With recent publications of the FASN crystal structure and the new development of FASN inhibitors, targeting FASN opens a new window of opportunity for metabolically combating cancers. In this article, we will review critically the recent progresses in understanding the structure, function, and the role of FASN in cancers and pharmacologically targeting FASN for human cancer treatment.",
keywords = "Cancer, Diagnosis, Drug resistance, Fatty acid synthase, Inhibitors, Prognosis",
author = "Hailan Liu and Liu, {Jing Yuan} and Xi Wu and Jian-Ting Zhang",
year = "2010",
language = "English",
volume = "1",
pages = "69--89",
journal = "International Journal of Biochemistry and Molecular Biology",
issn = "2152-4114",
publisher = "e-Century Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker

AU - Liu, Hailan

AU - Liu, Jing Yuan

AU - Wu, Xi

AU - Zhang, Jian-Ting

PY - 2010

Y1 - 2010

N2 - Human fatty acid synthase (FASN) is a 270-kDa cytosolic dimeric enzyme that is responsible for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for diagnosis and prognosis of human cancers. Recent studies showed that FASN is an oncogene and inhibition of FASN effectively and selectively kill cancer cells. With recent publications of the FASN crystal structure and the new development of FASN inhibitors, targeting FASN opens a new window of opportunity for metabolically combating cancers. In this article, we will review critically the recent progresses in understanding the structure, function, and the role of FASN in cancers and pharmacologically targeting FASN for human cancer treatment.

AB - Human fatty acid synthase (FASN) is a 270-kDa cytosolic dimeric enzyme that is responsible for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for diagnosis and prognosis of human cancers. Recent studies showed that FASN is an oncogene and inhibition of FASN effectively and selectively kill cancer cells. With recent publications of the FASN crystal structure and the new development of FASN inhibitors, targeting FASN opens a new window of opportunity for metabolically combating cancers. In this article, we will review critically the recent progresses in understanding the structure, function, and the role of FASN in cancers and pharmacologically targeting FASN for human cancer treatment.

KW - Cancer

KW - Diagnosis

KW - Drug resistance

KW - Fatty acid synthase

KW - Inhibitors

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79952148424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952148424&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 69

EP - 89

JO - International Journal of Biochemistry and Molecular Biology

JF - International Journal of Biochemistry and Molecular Biology

SN - 2152-4114

IS - 1

ER -